Well tolerated spironolactone-related hyponatremia

Journal of Clinical Hypertension

Volumn 10, Issue 4, 2008, Pages 317-321

  Handler, Joel ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; SPIRONOLACTONE;

AGED; CASE REPORT; CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; HYPONATREMIA; REVIEW; RISK FACTOR;

AGED, 80 AND OVER; DIURETICS; FEMALE; HUMANS; HYPONATREMIA; RISK FACTORS; SPIRONOLACTONE;

EID: 46349111987     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2008.08063.x     Document Type: Article

References (29)

1. Ouzan J, Perault C, Lincoff M, et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens. 2002;15:333-339.
2. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of lowdose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925-930.
3. Epstein M, Calhoun DA. The role of aldosterone in resistant hypertension: Implications for pathogenesis and therapy. Curr Hypertens Rep. 2007;9:98-105.
4. Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839-845.
5. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone. Hypertension. 2004;43:518-524.
6. Vogt B, Bochud M, Burnier M. The association of aldosterone with obesity-related hypertension and the metabolic syndrome. Semin Nephrol. 2007;27:529-537.
7. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older patients with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
8. Sharabi Y, Illan R, Kamari Y, et al. Diuretic induced hyponatremia in elderly hypertensive women. J Hum Hypertens. 2002;16:631-635.
9. Chow KM, Szeto CC, Wong TY-H, et al. Risk factors for thiazide-induced hyponatraemia. Q J Med. 2003;96:911-917.
10. Sica DA. Diuretic-related side effects: Development and treatment. J Clin Hypertens (Greenwich). 2004;6:532-540.
11. Hajjar I, Graves JW. Hyponatremia in older women. J Clin Hypertens (Greenwich). 2004;6:37-39.
12. Palmer BF, Naderi ASA. Metabolic complications associated with use of thiazide diuretics. J Am Soc Hypertens. 2007;1(6):381-392.
13. Sica DA. Hyponatremia and hear failure - Pathophysiology and implications. Congest Heart Fail. 2005;11:274-277.
14. Sonnenblick M, Friedlander Y, Rosin AJ. Diuretic-induced severe hyponatremia. Review and analysis of 129 reported patients. Chest. 1993;103:601-606.
15. Friedman E, Shadel M, Halkin H, et al. Thiazide-induced hyponatremia. Reproducibility by single dose rechallenge and an analysis of pathogenesis. Ann Intern Med. 1989;110:24-30.
16. Bouman WP, Pinner G, Johnson H. Incidence of selective serotonin reuptake inhibitor (SSRI) induced hyponatraemia due to the syndrome of inappropriate antidiuretic hormone (SIADH) secretion in the elderly. Int J Geriatr Psychiatry. 1998;13:12-15.
17. Sica DA. Hyponatremia and heart failure - Treatment considerations. Congest Heart Fail. 2006;12:55-60.
18. Sligl W, McAlister A, Ezekowitz J, et al. Usefulness of spironolactone in a specialized heart failure clinic. Am J Cardiol. 2004;94:443-447.
19. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol. 2003;41:211-214.
20. Hirschl MM, Seidler D, Laggner AN. Spironolactoneassisted hyponatremic coma. Nephron. 1994;67:503.
21. Sica DA. Angiotensin II and thirst: therapeutic considerations. Congest Heart Fail. 2001;7:325-328.
22. Renneboog B, Musch W, Vandemergel X, et al. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med. 2006;119:71.e1-71.e8.
23. Bissram M, Scott FD. Liu l, Rosner MH. Risk factors for symptomatic hyponatremia: the role of pre-existing asymptomatic hyponatremia. Intern Med J. 2007;37:149-155.
24. Wrenger E, Muller R, Moesenthin M, et al. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ. 2003;327:147-149.
25. Schepkens H, Vanholder R, Billiouw JM, et al. Lifethreatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med. 2001;110:438-441.
26. Blaustein DA, Babu K, Reddy A, et al. Estimation of glomerular filtration rate to prevent life-threatening hyperkalemia due to combined therapy with spironolactone and angiotensin converting enzyme inhibition or angiotensin receptor blockade. Am J Cardiol. 2002;90:662-663.
27. Cruz CS, Cruz AA , de Souza CAM. Hyperkalemia in congestive heart failure patients using ACE inhibitors and spironolactone. Nephrol Dial Transplant. 2003;18:1814-1819.
28. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol. 1996;78:902-907.
29. Obialo CI, Ofili E, Mirza T. Hyperkalemia in congestive heart failure patients aged 63-85 years with subclinical renal disease. Am J Cardiol. 2002;90:663-665.